Ameliorated pancreatic &amp;beta; cell dysfunction in type 2 diabetic patients treated with a sodium-glucose cotransporter 2 inhibitor ipragliflozin

Takahara, Mitsuyoshi; Shiraiwa, Toshihiko; Matsuoka, Taka‐aki; Katakami, Naoto; Shimomura, Iichiro

doi:10.1507/endocrj.ej14-0335

Cited by 51 publications

(51 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These data suggest that Ipra decreased HbA1c, reducing the overload on pancreatic β cells. As a previous report suggested, reduction of the pancreatic β cell load could result in improved pancreatic β cell function by Ipra [14]. Further, it was recently reported that too much insulin injection and consequent hyperinsulinemia might be a risk of cardiovascular events and cancer [15].…”

Section: Discussionmentioning

confidence: 92%

Efficacy and safety of sodium–glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION)

et al. 2018

View full text Add to dashboard Cite

Abstract. Sodium-glucose co-transporter-2 inhibitors are newly established anti-diabetic agents with a unique glucoselowering mechanism. In the present study, we investigated the efficacy and safety of the sodium-glucose co-transporter-2 inhibitor ipragliflozin (Ipra) for metabolic markers and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus (T2DM). This study was an investigator-initiated, open-label, single-arm, multicenter prospective study. Patients with T2DM were treated with 50 mg Ipra for 24 and 52 weeks. The primary outcome investigated was the reduction of glycated hemoglobin (HbA1c) level. The secondary outcome was the change in other metabolic and cardiovascular parameters by 24 weeks. Before and after 52 weeks of treatment, carotid intima-media thickening (IMT) was measured by echography. A total of 134 patients were recruited in the study. A 24-week treatment with 50 mg Ipra daily significantly reduced HbA1c level (-0.6%, p < 0.01). Body mass index (BMI), blood pressure and serum C-peptide were reduced significantly (p < 0.05), while serum glucagon level was unchanged. Interestingly, the serum adiponectin and high-density lipoprotein (HDL) cholesterol levels were significantly increased by Ipra. However, 52 weeks of Ipra treatment did not change carotid IMT. Multiple regression analysis revealed that the only significant contributing factor for HbA1c reduction by Ipra was baseline HbA1c level. These data suggest that Ipra decreased not only glucose level but also BMI, blood pressure and serum C-peptide, and the contributing factor for HbA1c reduction by Ipra was baseline HbA1c level. Further, Ipra improved serum adiponectin and HDL cholesterol levels.

show abstract

Section: Discussionmentioning

confidence: 92%

Efficacy and safety of sodium–glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION)

et al. 2018

View full text Add to dashboard Cite

show abstract

“…If the improved condition can be maintained for a long period of time, blood glucose-improving effects can be expected via reductions in insulin resistance in addition to the blood glucose-lowering effects through the promotion of urinary glucose excretion by SGLT2 inhibitory activity. Furthermore, considering the reports that ipragliflozin improved insulin sensitivity (as measured by a glucose tolerance test) at 4 weeks after the start of treatment (17) and that dapagliflozin improved the insulin sensitivity in the muscles (18), the treatment can also be expected to have protective effects on β-cells over the long term.…”

Section: Discussionmentioning

confidence: 99%

Sodium-glucose Co-transporter 2 Inhibitors Reduce the Abdominal Visceral Fat Area and May Influence the Renal Function in Patients with Type 2 Diabetes

et al. 2017

View full text Add to dashboard Cite

Objective and Methods An SGLT2 inhibitor (ipragliflozin, dapagliflozin, luseogliflozin, tofogliflozin, or canagliflozin) was administered to 132 outpatients with type 2 diabetes mellitus with or without other antidiabetic drugs for 6 months to evaluate its efficacy, the incidence of adverse events, and its influence on the renal function. Results The patient's mean glycated hemoglobin level significantly improved from 7.52±1.16% to 6.95± 0.98% (p<0.001). The body weight of the patients was significantly reduced from 78.0±15.3 kg to 75.6±15.1 kg (p<0.001). The estimated visceral fat area was also significantly reduced from 108.4±44.6 cm 2 to 94.5± 45.3 cm 2 (p<0.001). The waist circumference, blood pressure, serum alanine aminotransferase, γ-glutamyl transpeptidase, and uric acid levels also showed a significant decrease. The urinary albumin/creatinine ratio (U-ACR) was significantly reduced in the patients whose U-ACR levels were 30-300 mg/gCr at the baseline. The mean eGFR significantly decreased in the patients with a pre-treatment eGFR value of ! 90 mL/min/1.73 m 2 but remained unchanged in the patients with a pre-treatment value of <90 mL/min/1.73 m 2 . A total of 13 adverse events were noted, including systemic eruption (n=1), cystitis (n=2), pudendal pruritus (n=2), nausea (n=1), malaise (n=1), a strong hunger sensation and increased food ingestion (n=1), and non-serious hypoglycemia (n=5). Conclusion SGLT2 inhibitors seemed to be useful in the treatment of obese type 2 diabetes mellitus patients. Furthermore, these data suggest that SGLT2 inhibitors may protect the renal function.

show abstract

“…This clinical course suggests that replacement of IIT with OAD was appropriate for the patient. Recently, Takahara et al reported that a fourweek treatment with ipragliflozin improved the β-cell function and glucose levels in patients with type 2 diabetes mellitus, and these effects lasted even after discontinuance of ipragliflozin (11). In this case, an increase in UCPR was observed two weeks after starting ipragliflozin, however, it was several weeks before the UCPR levels increased to a sufficient level.…”

Section: Discussionmentioning

confidence: 73%

Fluctuation in Serum Sodium Levels Related to Ipragliflozin Administration in a Patient with Diabetic Nephropathy and Sequela of Traumatic Brain Injury

et al. 2016

View full text Add to dashboard Cite

A 46-year-old diabetic man underwent the removal of a hematoma caused by traumatic brain injury. After surgery, severe hyponatremia occurred. The subsequent administration of NaCl and fludrocortisone improved his laboratory findings. The patient was transferred to our hospital, and his insulin therapy was replaced by teneligliptin. One week later, ipragliflozin treatment was initiated and induced an immediate increase in the serum sodium levels. NaCl and fludrocortisone were therefore discontinued. However, hyponatremia recurred after ipragliflozin withdrawal due to a urinary tract infection. NaCl and fludrocortisone were initiated again, and the laboratory data improved. We herein report a case of serum sodium fluctuation related to ipragliflozin administration.

show abstract

Ameliorated pancreatic β cell dysfunction in type 2 diabetic patients treated with a sodium-glucose cotransporter 2 inhibitor ipragliflozin

Cited by 51 publications

References 36 publications

Efficacy and safety of sodium–glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION)

Efficacy and safety of sodium–glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION)

Sodium-glucose Co-transporter 2 Inhibitors Reduce the Abdominal Visceral Fat Area and May Influence the Renal Function in Patients with Type 2 Diabetes

Fluctuation in Serum Sodium Levels Related to Ipragliflozin Administration in a Patient with Diabetic Nephropathy and Sequela of Traumatic Brain Injury

Contact Info

Product

Resources

About